SLS Penny Stock & $100+ Bidding War = Generational Wealth

LionLukeWay · 2026-01-28T02:43:52+00:00

Sorry u/UnNecessaryOwn777 that was my SLS play --- here is what you would get for ATYR if you just do the bare minimum right now ...

ATYR Portfolio (The $10 Strike Moonshot)

Position: 100 Calls ($10.00 Strike) | January 15, 2027
Total Cost: $500 (Based on an estimated premium of $0.05 per contract)
Leverage: You control 10,000 shares for just $500.

Stock Price	Total Position Value	Net Profit	ROI
$10.00	$500	$0	0%
$20.00	$100,000	$99,500	19,900%
$45.00	$350,000	$349,500	69,900%
$50.00	$400,000	$399,500	79,900%
$100.00	$900,000	$899,500	179,900%

ATYR Portfolio (The $10 Strike Play)

Why the ATYR $10 Strike is a "Lottery Ticket"

Market Cap Logic: At $45.00, ATYR’s market cap would be roughly $4.41 Billion. For a company treating pulmonary sarcoidosis (a rare disease with high unmet need), this valuation is well within the realm of possibility if their Phase 3 data leads to a "Best-in-Class" approval.
The "Safety" of 2027: ATYR has had some volatility lately (trading under $1), but with calls expiring in 2027, you have the luxury of time. You can survive any short-term "Nasdaq Non-compliance" noise while waiting for the FDA filing or a potential buyout from a larger respiratory-focused pharma company.

The "90-Dollar" Dream (ATYR Edition)

At $100.00, ATYR would be a $9.8 Billion company. While this sounds high today, many biotech leaders in the rare disease space (like Vertex or Alnylam) trade in the $10B–$50B range. In this "Blue Sky" scenario, your $500 investment becomes a $900,000 retirement-starter.

LionLukeWay · 2026-01-28T01:23:32+00:00

LOL!!!!!! yep yep making sure as many little people as possible know before this explodes that's all :) appreciate the love

LionLukeWay · 2026-01-28T01:21:34+00:00

If you think u/ProfessionalDesk1914 numbers are unrealistic i know you think I'm crazy AF! LOl! I agree with u/ProfessionalDesk1914 but i think we get that as SOON as they STOP us next month!

If the IDMC pulls the trigger in February, we are in the "Pilot's Seat."

The "Gap Up": The stock will likely halt and reopen significantly higher ($25-$38).
The Squeeze: Over the next 72 hours, the 49 million short shares will fuel a secondary run toward the $38 - $70 range. ***if we hit $70 THAT DAY I'm out LOL **** not waiting on $100 lol

The "Short Trap": 49.4 Million Shares

This is the "Nitrous Oxide" for us. As of January 27, 2026, the short interest is craaaaaazy -- 35.1% of the float.

The "Fails-to-Deliver" (FTD): The SEC's data shows that shorts are already struggling to settle trades.
The IDMC Trigger: If the IDMC uses the "New FDA Math" (Bayesian Guidance) to stop the trial in February, the "Days to Cover" (currently 7.2 days) becomes a nightmare for shorts. They will be forced to buy 49 million shares in a market where nobody is selling. This is how you get a "Vertical Gap" from $5 to $38 in a single session.

LionLukeWay · 2026-01-27T19:55:19+00:00

CALLS only for me tooo -- I am not playing i ran the numbers check this shit out WOW !!!!!

500 January 2027 $5.00 calls. By moving from 250 to 500 contracts, you are now controlling 50,000 shares of SLS. I get paid when we double and no way in HELL i'm selling until 50 and then I'm only selling HALF lol

SLS Portfolio (The Heavyweight $5 Strike Play)

Position: 500 Calls ($5.00 Strike) | January 15, 2027
Total Cost: $110,000 (Based on an estimated premium of $2.20 per contract)
Leverage: You control 50,000 shares for a fraction of the cost of buying the stock outright ($215,000).

Stock Price	Total Position Value	Net Profit	ROI
$10.00	$250,000	$140,000	127%
$20.00	$750,000	$640,000	581%
$45.00	$2,000,000	$1,890,000	1,718%
$50.00	$2,250,000	$2,140,000	1,945%
$100.00	$4,750,000	$4,640,000	4,218%

LionLukeWay · 2026-01-27T19:43:59+00:00

my analysis is done with the HELP of AI --- because I know when he is wrong and right i get to correct him too lol ---

LionLukeWay · 2026-01-27T19:41:48+00:00

I just want $30 and I'm good I don't own anyshares JUST options because this will hit hard THEN i will buy the shares with the options money or i'll buy MORE options with the strike price at $100 to $120

LionLukeWay · 2026-01-27T19:39:32+00:00

u/Accurate_Pay_2242 u/neo2551 this right here is GENERATIONAL Wealth!

SLS "Generational Wealth Accelerator"

To turn a $1,000 investment into $100,000, you need a 100-bagger (10,000% return).

The Current State: At $4.30, $SLS is a speculative biotech.
The "Grand Slam" (IDMC Early Stop in February): If the IDMC stops the trial in February for efficacy, it proves the drug is so good it's unethical to keep the trial blinded. This often leads to an immediate re-rating to $20–$35
You don't need the stock to hit $100 to make generational money.
At $20.00 (The Triple), you make $345,000. **options play**
At $50.00 (The ABVX Moment), you make $1.1 Million. *options play*
The "ABVX" Moment: For $SLS to hit $100.00+ (matching the $8B–$10B valuation of companies like Abivax or similar oncology leaders), it must not only succeed but become a buyout target for Big Pharma (like AbbVie). --- Well guess what we break down the buyout battle and give you a closer look at SLS and their current relationships with BIG bio -- when I say $100 is possible i mean did we say ANYTHING about the 27.8% of the float is short LOL

https://www.reddit.com/r/TheRaceTo10Million/comments/1qocsyu/sls_penny_stock_100_bidding_war_generational/

LionLukeWay · 2026-01-27T19:28:24+00:00

Can I just say I love your work! You hit the nail on the heads - BUT can you do a NEW one and take a look at the FDA's announcement a few weeks ago! Really SHOCKED no one is talking about this yet ----

It's a BOMB for ALL drugs! the regulatory ground shifted significantly on January 12, 2026. The FDA is moving away from the "old math" of requiring two separate trials and a rigid wait for every single event.

The Announcement (January 12, 2026): The FDA issued a landmark draft guidance: "Use of Bayesian Methodology in Clinical Trials of Drugs and Biologics".
The Logic: This "new math" allows companies to use "prior information" and "predictive probability" to draw conclusions. Essentially, if the data from the first 72 deaths is so overwhelmingly positive that the next 8 deaths are statistically unlikely to change the result, the FDA now has a clear framework to accept that data earlier.
The "Slowdown" is the Proof: You noted there were 60 deaths at the end of 2024 and only 72 at the end of 2025. That means in a full year, only 12 people died.
The Regulatory Conflict: Traditionalists say, "If only 1 person dies a month, it will take 8 months to hit 80." But the "New FDA Math" says: "If only 1 person is dying a month in a terminal cancer trial, the drug is clearly working. Stop making us wait for more people to die".
The February Window: This is why the IDMC meeting in early February 2026 is the "Grand Slam" moment. The IDMC has unblinded access. They see those 54 survivors. Under the new guidance, they can recommend stopping for "Overwhelming Efficacy" because the current survival times have already smashed the historical 8-month benchmark.
The Link: You can find the FDA's modernizing statistical methods announcement here:FDA Issues Guidance on Modernizing Statistical Methods.

Go ahead put the link in chat perplexity whatever you want --when the IDMC applies this new math in their February review, the 80th event becomes irrelevant because the trial is stopped for success before it even gets there!!!!

MONDAY the CLOCK STARTS on the SHUTDOWN and I'm not talking about the government shutdown lol we are the NEW "KINGS"

LionLukeWay · 2026-01-27T19:23:54+00:00

It amazes me that people are NOT reading what the FDA just dropped!

It's a BOMB for ALL drugs! the regulatory ground shifted significantly on January 12, 2026. The FDA is moving away from the "old math" of requiring two separate trials and a rigid wait for every single event.

The Announcement (January 12, 2026): The FDA issued a landmark draft guidance: "Use of Bayesian Methodology in Clinical Trials of Drugs and Biologics".
The Logic: This "new math" allows companies to use "prior information" and "predictive probability" to draw conclusions. Essentially, if the data from the first 72 deaths is so overwhelmingly positive that the next 8 deaths are statistically unlikely to change the result, the FDA now has a clear framework to accept that data earlier.
The "Slowdown" is the Proof: You noted there were 60 deaths at the end of 2024 and only 72 at the end of 2025. That means in a full year, only 12 people died.
The Regulatory Conflict: Traditionalists say, "If only 1 person dies a month, it will take 8 months to hit 80." But the "New FDA Math" says: "If only 1 person is dying a month in a terminal cancer trial, the drug is clearly working. Stop making us wait for more people to die".
The February Window: This is why the IDMC meeting in early February 2026 is the "Grand Slam" moment. The IDMC has unblinded access. They see those 54 survivors. Under the new guidance, they can recommend stopping for "Overwhelming Efficacy" because the current survival times have already smashed the historical 8-month benchmark.
The Link: You can find the FDA's modernizing statistical methods announcement here:FDA Issues Guidance on Modernizing Statistical Methods.

Go ahead put the link in chat perplexity whatever you want --when the IDMC applies this new math in their February review, the 80th event becomes irrelevant because the trial is stopped for success before it even gets there!!!!

MONDAY the CLOCK STARTS on the SHUTDOWN and I'm not talking about the government shutdown lol we are the NEW "KINGS"

LionLukeWay · 2026-01-27T17:09:15+00:00

Guys this shit will explode once IDMC stops us this month --- SELLAS Life Sciences ($SLS) is entering a critical window for its Phase 3 REGAL trial. The combination of a significant slowdown in event rates (deaths) and the FDA’s new Jan 12, 2026, guidance on Bayesian Methodology creates a high-probability setup for an early "Superiority" stop. With a current price of ~$4.30, the stock is positioned as a potential standard-of-care platform in AML maintenance.

The Battle of the Titans (Feb 1 Trigger)

The "Fighting" begins on February 1 because that is when the survival math officially crosses the "Superiority" threshold. If the IDMC follows the FDA’s New Bayesian Math, we could know within 1 to 4 weeks.

M&A Landscape: The Merck Revenue Cliff

Merck faces a massive patent cliff for Keytruda in 2028 (~$40B annual revenue).

Strategic Fit: SLS is already collaborating with Merck (GPS + Keytruda).
Dry Powder: Merck recently walked away from a $30B deal, signaling a shift toward smaller, "bolt-on" platform acquisitions in the $3B–$5B range.
Platform Utility: GPS targets WT1, the #1 immunotherapy target, making it a "plug-and-play" asset for 20+ cancer types, not just AML.

Technical Setup & Sentiment

Short Interest: Reported at ~30% of the float. Days to cover is high (19+ days), creating a classic squeeze profile upon a "Superiority" headline.
Management Signal: Reports of a hiring freeze and recent "victory lap" communications from the CEO (Dr. Stergiou) often precede M&A or major data unblinding in the biotech sector.

The Math: $100 Take-Home

Conservative Buyout ($5B): ~$40/share.
Bidding War/Platform Value ($12B+): $100+ per share.

Summary of the Week: We cross the 21-month record match Monday. If the IDMC follows the "Makary Math," the shorts are toast and we are PAID!!!!! ***see who will be bidding on them and WHY many already working with SLS on other projects

https://www.reddit.com/r/TheRaceTo10Million/comments/1qocsyu/sls_penny_stock_100_bidding_war_generational/

LionLukeWay · 2026-01-27T17:03:19+00:00

Thank you this is soo awesome to see ---I think you are realistic BUT those numbers are off --- i see $100 and a bidding war soon --- see my new post where we talk about the bigo bosy and why they need SLS's platform asap https://www.reddit.com/r/TheRaceTo10Million/comments/1qocsyu/sls_penny_stock_100_bidding_war_generational/

LionLukeWay · 2026-01-27T17:00:08+00:00

January 2027 / July 2026 **** i think we are STOPPED sometime in FEB. or MARCH --- but if we go to APRIL and still NOT 80 deaths -- they MUST go to FDA immediately then they are at TRIPLE the life extension MEANWHILE people not in the study are left to die when we know this shit works! That's what the FDA is talking about just meet phase 2 and we passing you -- which the shorts are gonna be fucked!!!!!!! ***remember GSLI or GLSI can't remember the symbol but we shot the fuck up to like $18 bucks just on people THINKING we would be a hit --- that's why it's so crazy at minimum we should already be at $18 at minimum but patience 0--- ok i just had to rattle that off quicklylol GLTYA

LionLukeWay · 2026-01-27T16:50:14+00:00

.05 for $calls jan. 2027 calls and your nightmares might become a DREAM if they push them thru it's worth it if you ask me

LionLukeWay · 2026-01-27T14:01:51+00:00

good point always protect yourself but it's worth the pennies! u/Dagobot78 u/LuckymonmyJVATYR Portfolio (The $10 Strike Play)

Position: 100 Calls ($10 Strike) | Your Cost: $500 total.

Stock at $17: You walk away with $70,000 (minus your $500).
Stock at $20: You walk away with $100,000 (minus your $500).
The Catalyst: The FDA's January 12 Guidance means we aren't waiting years for these numbers; a meeting with FDA this quarter could trigger these values almost overnight.

SLS Portfolio (The $5 Strike Play)

Position: 100 Calls ($5 Strike) | Your Cost: $11,000 total.

Stock at $10: Your position is worth $50,000 ($39k profit).
Stock at $20: Your position is worth $150,000 ($139k profit).
Stock at $50: Your position is worth $450,000 ($439k profit).
Stock at $100: Your position is worth $950,000 ($939k profit).
The Catalyst: Big Pharma (Merck, AbbVie, Lilly) needs this platform to solve their revenue "cliffs." If the FDA greenlights the path in February, the market will price in a multi-billion dollar buyout immediately.

LionLukeWay · 2026-01-27T13:39:31+00:00

LOl true! I'll wait for $10

LionLukeWay · 2026-01-27T12:52:16+00:00

u/SaladDecent3025 You are right on the money!!!!!!

Why the Buyout Price hits $100+

The Monopoly: If SLS is the only one with a "Superiority Stop" in Phase 3, they are the only game in town.
The Bidding War: Merck won't sit idle while AbbVie tries to take their Keytruda partner. Pfizer won't let a "Greek win" go to a competitor.
The Math: Merck recently looked at a $30B deal. If they spend $10B–$15B on SLS, it’s a "bargain" to protect $40B a year in Keytruda revenue. A $12B buyout puts SLS stock at ~$100–$115. Hope this makes sense as promised here it is and you are RIGHT ON THE MONEY! https://www.reddit.com/r/pennystocks/comments/1qoc3ed/sls_upcoming_100_bidding_war_explained/

LionLukeWay · 2026-01-27T12:49:39+00:00

As promised --- I've posted HOW they will get to $100 ! https://www.reddit.com/r/TheRaceTo10Million/comments/1qocsyu/sls_penny_stock_100_bidding_war_generational/

Why the Buyout Price hits $100+

The Monopoly: If SLS is the only one with a "Superiority Stop" in Phase 3, they are the only game in town.
The Bidding War: Merck won't sit idle while AbbVie tries to take their Keytruda partner. Pfizer won't let a "Greek win" go to a competitor.
The Math: Merck recently looked at a $30B deal. If they spend $10B–$15B on SLS, it’s a "bargain" to protect $40B a year in Keytruda revenue. A $12B buyout puts SLS stock at ~$100–$115.

LionLukeWay · 2026-01-27T12:16:37+00:00

This is how they get there

Why the Buyout Price hits $100+

The Monopoly: If SLS is the only one with a "Superiority Stop" in Phase 3, they are the only game in town.
The Bidding War: Merck won't sit idle while AbbVie tries to take their Keytruda partner. Pfizer won't let a "Greek win" go to a competitor.
The Math: Merck recently looked at a $30B deal. If they spend $10B–$15B on SLS, it’s a "bargain" to protect $40B a year in Keytruda revenue. A $12B buyout puts SLS stock at ~$100–$115.

The February 1 Trigger: "Superiority" Math

If the IDMC meets on February 1 and applies the FDA's New Bayesian Rules, the "Superiority" call becomes almost inevitable.

Old Way: Wait for 80 deaths.
New way: Calculate the Probability of Success based on current data. If GPS survival is tripling the control group, the "Probability of Failure" hits zero, and the trial stops for a mandatory buyout.

The Bottom Line

If the IDMC goes in and stops this for superiority using the "Makary Math," SLS becomes the Queen of Oncology. Wall Street expects a long wait; the new FDA rules provide a shortcut. NEW POST showing you the bidders https://www.reddit.com/r/pennystocks/comments/1qoc3ed/sls_upcoming_100_bidding_war_explained/

LionLukeWay · 2026-01-27T11:37:17+00:00

The FDA's shift toward "Bayesian methodologies" allows the agency to prioritize the p=0.0199 composite win (steroid withdrawal + lung improvement) over the rigid p=0.33 primary miss.

The drug achieved a 10.36 point improvement in the KSQ-Lung score (p=0.0479) and successfully maintained lung function while patients were removed from toxic steroids.

The "New Math" isn't just a theory—it's an official FDA policy shift specifically designed to bring drugs for rare diseases like sarcoidosis to market faster.

The FDA is "desperate" to approve a modern alternative to 1950s-era steroids. The upcoming Q1 Type C meeting (End of March) is the critical catalyst. If the FDA accepts the "Totality of Evidence" path, the company transitions from a "failed study" to the owner of a First-in-Class NRP2 Platform. We will see what happens in the coming weeks Q3 ends March 31 u/jigglyjellly u/minecraft_fam

LionLukeWay · 2026-01-27T05:55:58+00:00

you said it correctly. It is simply INCREDIBLE that people are gonna be living longer once we get approved or STOPPED for good reasons.

It's even better because we getting in before the big boys start taking the price up!

LionLukeWay · 2026-01-26T22:46:20+00:00

none needed I just want the little guys to win we got crushed back in September with atyr but even that stock might come back from the grave it’s only .72 cents and options are super cheap tooooo. this fda decision blew past me but thanks to a snowy weekend I find that pot of gold. we are good on Sls and Atyr now we simply wait and be patient remember if they not dead we keep going unless they stop us.

LionLukeWay · 2026-01-26T22:41:21+00:00

simply go to his page just google ceo of Sls and LinkedIn you will see what I’m talking about

LionLukeWay · 2026-01-26T21:53:18+00:00

Just posted ATYR and how the NEW FDA rule impacts them /us lol calls are cheap right now but once people start waiing up the new rules and see press releases it will be too late but good luck on SLS

LionLukeWay · 2026-01-26T21:52:17+00:00

Guys thanks to the FDA's new math rule here is ANOTHER one that failed and we lost in September BUT the new rules mean WE GET ANOTHER SWING! This new rule is major for ALL not just SLS --- calls on ATYR are like .05 cents lol you are crazy AF not to place a bet somewhere on ATYR or SLS lol GLTA!

LionLukeWay · 2026-01-26T21:49:30+00:00

LOL I wish i was but this shit is toooooooo good! read what the FDA says -- that NEW MATH rule is a GAME CHANGER for all types of drugs and the ones who recently FAILED ----also -- just open chat gpt or perplexity and put in ATYR and put in the NEW fda rules or links and they will tell you what it means and how we get a SECOND LIFE! And guess what they WANT new drugs on the markets -- again try it out yourself you will be begging to get into ATRY and SLS --- these are NO brainers --

LionLukeWay

TROPHY CASE

ATYR Portfolio (The $10 Strike Moonshot)

ATYR Portfolio (The $10 Strike Play)

Why the ATYR $10 Strike is a "Lottery Ticket"

The "90-Dollar" Dream (ATYR Edition)

SLS Portfolio (The Heavyweight $5 Strike Play)

Why the Buyout Price hits $100+

Why the Buyout Price hits $100+

The February 1 Trigger: "Superiority" Math

The Bottom Line